Overview


According to FutureWise analysis the market for desmoid tumor in 2023 is US$ 3.06 billion, and is expected to reach US$ 4.63 billion by 2031 at a CAGR of 5.32%.

The desmoid tumor can be a rare condition. Desmoid tumors develop from cells called fibroblasts. These cells can be found all over the body and provide structural support, protection, and a crucial role in wound healing. Although most often found in women in their thirties and thirties these tumors can occur at any age. They can grow slowly or become malignant. But, fibromatosis aggressively can cause serious complications and even death. It is a localized form of disease that compresses vital organs like the intestines. Although most cases are not serious, there are some cases that are linked to familial FAB polyposis. Desmoid tumors are found in approximately 10% of Gardner's Syndrome patients. There are three types of desmoid tumors: extra-abdomen, stomach wall, and intra-abdominal. The latter is more common for patients with FAP. The lesions can be related to estrogen or trauma/ procedures. A 3' APC mutation in FAP patients is the leading risk factor for intra-abdominal desmoid formation. FAP patients who have an abdominal wall desmoid prior to surgery are at an increased chance of developing an intra-abdominal desmoid. Breast desmoid tumors are uncommon. Although benign, desmoid tumors of the breast can mimic breast carcinoma on physical examination, mammography, and breast ultrasound. They can also be localized invasive. Although they may only occur occasionally, they can also be diagnosed as part of Gardner’s syndrome. Rare lesions, such as desmoid tumors of the breast, require a high level of suspicion and a triple exam protocol. A desmoid tumor of the breast can be difficult to diagnose, especially when imaging studies are not conclusive. This could lead to a more grave diagnosis. Waiting, surgical Removal, radiation treatment, and antiestrogens may be used. Tamoxifen NSAIDs or treatment (cold/heat, ultrasound). A multi-disciplinary team including surgeons, radiologists, medical oncologists, geneticists, and radiation oncologists should evaluate patients with desmoid tumors. There is no cure for desmoid tumors. Patients should consider enrolling in clinical trials if possible.

A biopsy is the only way to definitively determine the type of tumor. The main problem with these lesions is the high incidence of recurrences in FAP-associated diseases. For intra-abdominal fibrosis, even if there is no evidence of FAP, it appears that the risk of recurrence for this condition is lower. To reduce the risk of recurrence, wide surgical resection is the most commonly used technique. This can be done with either radiation, chemotherapy, or hormonal therapy.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Desmoid Tumor Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Desmoid Tumor Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Amgen Inc.
  • Novartis AG
  • Abbott Laboratories
  • Bayer AG
  • Abbvie Inc
  • Beckman Coulter Inc
  • Stryker Corporation
  • Debiopharm group
  • F.Hoffmann-La Roche Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Diagnosis

  • Biopsy
  • Electron Microscopic Examination
  • Immunohistochemical Analysis
  • Others

By Treatment

  • Surgery
  • Radiation Therapy
  • Anti-inflammatory Medication
  • Hormone Therapy
  • Chemotherapy
  • Novel Molecular-targeted Therapy
    • Gleevec-based Therapy
    • Sorafenib-based Therapy
  • Others

By End User

  • Hospitals and Clinics
  • Specialty Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Desmoid Tumor Market By Diagnosis, By Treatment, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Desmoid Tumor Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Desmoid Tumor Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Desmoid Tumor Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Desmoid Tumor Market, By Diagnosis Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Biopsy
        2. Electron Microscopic Examination
        3. Immunohistochemical Analysis
        4. Others

  • 8.   Desmoid Tumor Market, By Treatment Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Surgery
        2. Radiation Therapy
        3. Anti-inflammatory Medication
        4. Hormone Therapy
        5. Chemotherapy
        6. Novel Molecular-targeted Therapy
         6.1. Gleevec-based Therapy
         6.2. Sorafenib-based Therapy
        7. Others

  • 9.   Desmoid Tumor Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals and Clinics
        2. Specialty Centers
        3. Others

  • 10.   North America Desmoid Tumor Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.   Latin America Desmoid Tumor Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.   Europe Desmoid Tumor Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.   Asia Pacific Desmoid Tumor Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Amgen Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Abbott Laboratories
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bayer AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Abbvie Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Beckman Coulter Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Stryker Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Debiopharm group
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. F.Hoffmann-La Roche Ltd
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients